Operational tolerance can be predicted noninvasively using a biomarker panel, indicating promising advances in liver transplantation.
Key evidence includes the potential for safely achieving immunosuppressive (IS) therapy withdrawal in liver transplant recipients.
Assessment utilized a peripheral blood transcriptional biomarker panel to identify the propensity for spontaneous operational tolerance.
The findings support a shift towards noninvasive methods, but external validation is necessary to confirm accuracy and reliability.
Abstract
This model might make it feasible to non-invasively identify the propensity to achieve spontaneous OT among liver recipients undergoing IS therapy and safely achieve IS withdrawal.